As of right now, Johnson & Johnson [JNJ] is trading at $151.13, up 0.05%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The JNJ shares have lost -1.88% over the last week, with a monthly amount drifted -4.21%, and not seem to be holding up well over a long-time horizon.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
On 15, March 2023, Johnson & Johnson to Host Investor Conference Call on First-Quarter Results. In a post published today on Yahoo Finance, Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 18th to review first-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.
From an analyst’s perspective:
Johnson & Johnson [NYSE: JNJ] stock has seen the most recent analyst activity on March 01, 2023, when Guggenheim initiated its Neutral rating and assigned the stock a price target of $161. Previously, Credit Suisse started tracking the stock with Neutral rating on November 18, 2022, and set its price target to $170. On October 18, 2022, Barclays initiated with a Equal Weight rating and assigned a price target of $175 on the stock. BofA Securities reiterated its Neutral rating and decreased its price target to $178 on October 14, 2022. Daiwa Securities initiated its recommendation with a Outperform.
Through the last year, Johnson & Johnson’s stock price ranged from $150.71 to $186.69. Currently, Wall Street analysts expect the stock to reach $179.68 within the next 12 months. Johnson & Johnson [NYSE: JNJ] shares were valued at $151.13 at the most recent close of the market. An investor can expect a potential return of 18.89% based on the average JNJ price forecast.
Analyzing the JNJ fundamentals
For Johnson & Johnson, (JNJ), the latest quarter sales were 23.72 billion, which represents an -4.40% decrease. In the same period, the company’s revenue per employee was $622,233, whereas its income per employee was $117,492. Gross Margin for this corporation currently stands at +67.67% with Operating Margin at +26.08%, Pretax Margin comes in at +22.86%, and Net Margin reading is +18.88%. To continue investigating profitability, this company’s Return on Assets is posted at 9.71, Equity is 23.79, Total Capital is 21.88, and Invested Capital is 17.09. An extended look at the Principal structure reveals enduring liabilities to the total capital of 34.78 and enduring liabilities to assets of 21.86.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 150.26 points at the first support level, and at 149.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 151.84, and for the 2nd resistance point, it is at 152.56.
Johnson & Johnson [JNJ] reported earnings per share of $2.35 for its fiscal quarter that ended on 12/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $2.23/share, meaning a difference of $0.12 and a surprise factor of 5.40%. By comparison, the stated earnings for the previous quarter ended on 9/29/2022 were $2.55 per share as compared to estimates of $2.47 per share, a difference of $0.08 representing a surprise of 3.20%.
Ratios To Look Out For
It is important to note that Johnson & Johnson [NYSE:JNJ] has a current ratio of 1.00. Further, the Quick Ratio stands at 0.77, while the Cash Ratio is 0.42. Considering the valuation of this stock, the price to sales ratio is 4.95, the price to book ratio is 6.01 and the P/E (TTM) ratio is 22.43.
Transactions by insiders
Insider trading, which has resulted in 26 insider purchases of 875,280 shares and 26 insider sales of 541,227 shares in the past three months, is now the topic of our analysis. Recent insider trading involved Swanson James D.,, that happened on Mar 06 when 1062.0 shares were sold. Exec VP, CFO, Wolk Joseph J completed a deal on Dec 13 to sell 14781.0 shares. Meanwhile, EVP, WW Chair, MedTech McEvoy Ashley sold 73323.0 shares on Nov 30.